CHFR and cancer: If the PFS was not improved in patients with promoter methylation of CHFR in cancer tissues, this may indicate that promoter methylation of CHFR can be a specific and favorable biomarker to irinotecan while it can basically be a negative prognostic factor for CRC, especially when it appears in ctDNA.